Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab

Mult Scler Relat Disord. 2020 Sep:44:102341. doi: 10.1016/j.msard.2020.102341. Epub 2020 Jun 26.

Abstract

Background: It is unknown whether MS disease modifying therapies impact ability to mount an antibody response to SARS-CoV-2.

Methods: Case series and literature review. We report a series of two MS patients who developed COVID-19 while on Ocrelizumab therapy and subsequently exhibited negative SARS-CoV-2 serology.

Results: A 42-year-old man and 39-year-old woman with MS developed COVID-19 while on Ocrelizumab therapy. Neither patient required hospitalization. The man exhibited negative serology at 7- and 9-weeks post-infection. The woman exhibited negative serology at 6- and 12-weeks post-infection.

Conclusions: Large studies are essential to determine whether certain DMTs may blunt SARS-CoV-2 antibody production.

Keywords: Antibodies; COVID-19; Coronavirus; Multiple sclerosis; Ocrelizumab.

Publication types

  • Case Reports
  • Letter
  • Review

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • COVID-19 / complications
  • COVID-19 / diagnosis*
  • COVID-19 Serological Testing*
  • Female
  • Humans
  • Immunologic Factors / therapeutic use*
  • Male
  • Multiple Sclerosis / complications
  • Multiple Sclerosis / drug therapy*

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • ocrelizumab